Personalized treatment of 95 poorly differentiated thyroid cancer/anaplastic thyroid cancer in 2019–2023
Despite the generally poor prognosis, aggressive treatment, particularly neoadjuvant therapy, has been shown to improve survival. Personalized treatment is crucial for optimizing treatment strategies for PDTC/ATC.
Authors
- Yulong Wang (ORCID: https://orcid.org/0000-0002-3830-7257)
- Qing Guan (ORCID: https://orcid.org/0000-0003-4687-4275)
- Yunjun Wang
- Jia-ying Chen
- Jia‐Qian Hu (ORCID: https://orcid.org/0000-0002-0142-6498)
- Naisi Huang (ORCID: https://orcid.org/0000-0001-7623-5744)
- Yu Wang (ORCID: https://orcid.org/0009-0009-1735-0473)
- Dongmei Ji (ORCID: https://orcid.org/0000-0003-0647-0153)
- Wanlin Liu (ORCID: https://orcid.org/0000-0001-6944-0547)
- Wenjun Wei (ORCID: https://orcid.org/0009-0002-5809-8816)
- Jun Xiang (ORCID: https://orcid.org/0000-0002-3425-0097)
- Qinghai Ji (ORCID: https://orcid.org/0000-0002-4376-0937)
- Tuanqi Sun (ORCID: https://orcid.org/0000-0001-6521-4550)
Institutions
- Shanghai Medical College of Fudan University (CN)
- Fudan University Shanghai Cancer Center (CN)
Publication Details
- Journal
- European Thyroid Journal
- Published
- 2025-10-17
- DOI
- https://doi.org/10.1530/etj-24-0371
- Citations
- 2
- Primary Topic
- Thyroid Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 2.59